Novo Nordisk and Amazon Web Services Launch AI Co-Innovation Hub in London for Drug Discovery

Aug 10, 2026

Novo Nordisk and Amazon Web Services (AWS) announced a strategic partnership on August 10, 2026, establishing an AI co-innovation hub in London to accelerate drug discovery. Under the agreement, AWS becomes Novo Nordisk's preferred cloud provider and strategic AI partner. The collaboration leverages platforms like Amazon Bio Discovery and Amazon Bedrock to identify drug targets and has already reduced clinical documentation times for over 25,000 employees. This deal expands Novo Nordisk's growing AI portfolio, which also includes partnerships with NVIDIA and OpenAI.

London AI co-innovation hub

▪As part of their partnership, Novo Nordisk and Amazon Web Services established an AI co-innovation hub within Novo Nordisk's existing facility in London.
▪The London co-innovation hub brings together Amazon Web Services engineers, AI specialists, and applied scientists alongside Novo Nordisk research and development teams.
▪Novo Nordisk and Amazon Web Services announced a strategic partnership on August 10, 2026, to accelerate drug discovery and modernize operations using agentic AI and cloud technologies.

AWS preferred cloud provider

▪Novo Nordisk selected Amazon Web Services as its preferred cloud provider and strategic AI partner to modernize its technology infrastructure.
▪The agreement builds on a multi-year relationship between Novo Nordisk and Amazon Web Services that includes early data infrastructure projects and a generative AI platform built on Amazon Bedrock.

Amazon Bio Discovery platform

▪Novo Nordisk will utilize Amazon Bio Discovery, which offers AI models trained on biological datasets, and Amazon Bedrock to identify drug targets and design therapies.
▪Novo Nordisk will deploy Amazon Bedrock AgentCore, a managed infrastructure platform, to drive operational efficiencies through AI agents.

Clinical documentation time reduction

▪The collaboration between Novo Nordisk and Amazon Web Services has already reduced clinical documentation time and boosted productivity for more than 25,000 employees.
▪Novo Nordisk collaborates with other Amazon businesses, including Amazon Pharmacy, Amazon Ads, and Amazon One Medical, to transform how therapies are marketed and delivered.

Multiple AI partnership portfolio

▪In April 2026, Novo Nordisk announced a partnership with OpenAI to use its technologies across drug discovery, manufacturing, and commercial functions, and was named an early collaborator on GPT-Rosalind.
▪Novo Nordisk has established other AI partnerships, including a 2025 agreement with NVIDIA to build customized AI models and support its use of the Gefion sovereign AI supercomputer.
▪Amazon Web Services has signed other 2026 AI drug discovery partnerships, including collaborations with Flagship Pioneering and Johnson & Johnson.